We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Shares of Patterson Companies, Inc. (PDCO - Free Report) scaled a new 52-week high of $34.46 on Aug 15, before closing the session slightly lower at $33.83.
Over the past year, this Zacks Rank #1 (Strong Buy) stock has gained 14.5% compared with the 11.2% rise of the industry and the S&P 500’s 4.2% growth.
Over the past five years, the company registered earnings growth of 6% compared with the industry’s 8.8% rise. The company’s long-term expected growth rate of 9.2% compares with the industry’s growth projection of 12.2%. Patterson Companies’ earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters and missed once, the average surprise being 4.5%.
Patterson Companies is witnessing an upward trend in its stock price, prompted by its broad product line. The optimism led by a solid third-quarter fiscal 2023 performance and a few notable acquisitions are expected to contribute further. Integration risks and stiff competitive forces persist.
Image Source: Zacks Investment Research
Let’s delve deeper.
Key Growth Drivers
Broad Product Spectrum: We are optimistic about Patterson Companies’ wide range of consumable supplies, equipment and software, and value-added services. A notable offering from the company is a private-label brand named Pivotal, while it continues adding stock-keeping units to its broader private-label portfolio. Patterson Companies’ NaVetor is an integrated cloud-based veterinary practice management software for its Animal Health segment.
Acquisitions: We are upbeat about Patterson Companies’ strategy of expanding its business via strategic acquisitions. In January, it announced that it had, through subsidiaries, completed the previously-announced acquisition of substantially all the assets of Relief Services for Veterinary Practitioners and Animal Care Technologies.
In December 2022, Patterson Companies announced that it had, through a subsidiary, closed the previously announced acquisition of substantially all the assets of Dairy Tech, Inc.
Strong Q3 Results: Patterson Companies’ better-than-expected earnings in third-quarter fiscal 2023 results buoy optimism. Strength in the overall top line, value-added Services and Other business of the Dental segment and the overall Animal Health segment was witnessed. The gross margin expansion bodes well for the company. Prudent cost-saving initiatives and solid sales execution continue to favor Patterson Companies.
Downsides
Stiff Competition: The U.S. dental products distribution industry is highly competitive and consists chiefly of national, regional and local full-service and mail-order distributors. Patterson Companies needs to continue to introduce newer products in the market to withstand competitive pressures. Failure to do so can dilute the company’s market share.
Integration Risks: Patterson Companies has been on an acquisition spree which is improving its revenue opportunities, but aggravating integration risks. Regular acquisitions are also a distraction for management, which is likely to impact organic growth. This may limit Patterson Companies’ future expansion and worsen the company’s risk profile, going forward.
Other Key Picks
A few other top-ranked stocks in the broader medical space are Cardinal Health, Inc. (CAH - Free Report) , HealthEquity, Inc. (HQY - Free Report) and McKesson Corporation (MCK - Free Report) .
Cardinal Health, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 13.5%. CAH’s earnings surpassed estimates in all the trailing four quarters, with an average surprise of 16%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Cardinal Health has gained 31.1% compared with the industry’s 11.2% rise over the past year.
HealthEquity, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 22%. HQY’s earnings surpassed estimates in three of the trailing four quarters and missed once, with an average of 9.1%.
HealthEquity has gained 13.3% against the industry’s 15.2% decline over the past year.
McKesson, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 10.7%. MCK’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 8.1%.
McKesson has gained 17.3% compared with the industry’s 11.2% rise over the past year.
See More Zacks Research for These Tickers
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Patterson Companies (PDCO) Hits 52-Week High: What's Aiding It?
Shares of Patterson Companies, Inc. (PDCO - Free Report) scaled a new 52-week high of $34.46 on Aug 15, before closing the session slightly lower at $33.83.
Over the past year, this Zacks Rank #1 (Strong Buy) stock has gained 14.5% compared with the 11.2% rise of the industry and the S&P 500’s 4.2% growth.
Over the past five years, the company registered earnings growth of 6% compared with the industry’s 8.8% rise. The company’s long-term expected growth rate of 9.2% compares with the industry’s growth projection of 12.2%. Patterson Companies’ earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters and missed once, the average surprise being 4.5%.
Patterson Companies is witnessing an upward trend in its stock price, prompted by its broad product line. The optimism led by a solid third-quarter fiscal 2023 performance and a few notable acquisitions are expected to contribute further. Integration risks and stiff competitive forces persist.
Image Source: Zacks Investment Research
Let’s delve deeper.
Key Growth Drivers
Broad Product Spectrum: We are optimistic about Patterson Companies’ wide range of consumable supplies, equipment and software, and value-added services. A notable offering from the company is a private-label brand named Pivotal, while it continues adding stock-keeping units to its broader private-label portfolio. Patterson Companies’ NaVetor is an integrated cloud-based veterinary practice management software for its Animal Health segment.
Acquisitions: We are upbeat about Patterson Companies’ strategy of expanding its business via strategic acquisitions. In January, it announced that it had, through subsidiaries, completed the previously-announced acquisition of substantially all the assets of Relief Services for Veterinary Practitioners and Animal Care Technologies.
In December 2022, Patterson Companies announced that it had, through a subsidiary, closed the previously announced acquisition of substantially all the assets of Dairy Tech, Inc.
Strong Q3 Results: Patterson Companies’ better-than-expected earnings in third-quarter fiscal 2023 results buoy optimism. Strength in the overall top line, value-added Services and Other business of the Dental segment and the overall Animal Health segment was witnessed. The gross margin expansion bodes well for the company. Prudent cost-saving initiatives and solid sales execution continue to favor Patterson Companies.
Downsides
Stiff Competition: The U.S. dental products distribution industry is highly competitive and consists chiefly of national, regional and local full-service and mail-order distributors. Patterson Companies needs to continue to introduce newer products in the market to withstand competitive pressures. Failure to do so can dilute the company’s market share.
Integration Risks: Patterson Companies has been on an acquisition spree which is improving its revenue opportunities, but aggravating integration risks. Regular acquisitions are also a distraction for management, which is likely to impact organic growth. This may limit Patterson Companies’ future expansion and worsen the company’s risk profile, going forward.
Other Key Picks
A few other top-ranked stocks in the broader medical space are Cardinal Health, Inc. (CAH - Free Report) , HealthEquity, Inc. (HQY - Free Report) and McKesson Corporation (MCK - Free Report) .
Cardinal Health, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 13.5%. CAH’s earnings surpassed estimates in all the trailing four quarters, with an average surprise of 16%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Cardinal Health has gained 31.1% compared with the industry’s 11.2% rise over the past year.
HealthEquity, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 22%. HQY’s earnings surpassed estimates in three of the trailing four quarters and missed once, with an average of 9.1%.
HealthEquity has gained 13.3% against the industry’s 15.2% decline over the past year.
McKesson, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 10.7%. MCK’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 8.1%.
McKesson has gained 17.3% compared with the industry’s 11.2% rise over the past year.